AR073770A1 - Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden - Google Patents
Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprendenInfo
- Publication number
- AR073770A1 AR073770A1 ARP090103832A ARP090103832A AR073770A1 AR 073770 A1 AR073770 A1 AR 073770A1 AR P090103832 A ARP090103832 A AR P090103832A AR P090103832 A ARP090103832 A AR P090103832A AR 073770 A1 AR073770 A1 AR 073770A1
- Authority
- AR
- Argentina
- Prior art keywords
- fgfr
- human
- seq
- sequence
- receptor
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 3
- 230000015556 catabolic process Effects 0.000 title abstract 2
- 238000006731 degradation reaction Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 title 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 title 3
- 229940126864 fibroblast growth factor Drugs 0.000 title 3
- 239000000203 mixture Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 4
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 4
- 101000917148 Homo sapiens Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19685508P | 2008-10-20 | 2008-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073770A1 true AR073770A1 (es) | 2010-12-01 |
Family
ID=42062445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103832A AR073770A1 (es) | 2008-10-20 | 2009-10-05 | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8043618B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2342232A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5577345B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101370798B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN103524620A (cg-RX-API-DMAC7.html) |
| AR (1) | AR073770A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009307841B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0919832A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2741127C (cg-RX-API-DMAC7.html) |
| EA (1) | EA021584B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL211807A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011004317A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ592369A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI381848B (cg-RX-API-DMAC7.html) |
| UA (1) | UA101681C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010048026A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201101938B (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI381848B (zh) * | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
| PE20120553A1 (es) | 2009-03-25 | 2012-05-18 | Genentech Inc | Anticuerpos anti-fgfr3 |
| WO2013088191A1 (en) | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| MX2015011428A (es) | 2013-03-06 | 2016-02-03 | Genentech Inc | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. |
| TWI541022B (zh) * | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法 |
| WO2015148708A1 (en) | 2014-03-25 | 2015-10-01 | Regeneron Pharmaceuticals, Inc. | Fgf21 receptor agonists and uses thereof |
| WO2015187521A2 (en) * | 2014-06-03 | 2015-12-10 | Merck Sharp & Dohme Corp. | Anti-blys antibodies |
| CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
| EP3189341A4 (en) * | 2014-09-05 | 2018-05-02 | Hyperfine Research Inc. | Ferromagnetic augmentation for magnetic resonance imaging |
| HUE058219T2 (hu) | 2014-09-26 | 2022-07-28 | Janssen Pharmaceutica Nv | FGFR-mutánsgénpanel alkalmazása olyan rákbetegek azonosításában, akik FGFR-inhibitorral történõ kezelésre reszponzívak lesznek |
| CN107635583A (zh) * | 2015-02-19 | 2018-01-26 | 生物临床医疗公司 | 用于治疗癌症的方法、组合物和试剂盒 |
| EP3265462A1 (en) | 2015-03-03 | 2018-01-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Fgfr3 antagonists |
| TW201711702A (zh) * | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法 |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| EP3481859B1 (en) | 2016-07-07 | 2022-04-13 | Pfizer Inc. | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
| US20180244785A1 (en) * | 2017-01-09 | 2018-08-30 | Merrimack Pharmaceuticals, Inc. | Anti-fgfr antibodies and methods of use |
| US11505611B2 (en) | 2020-08-21 | 2022-11-22 | Genzyme Corporation | FGFR3 antibodies and methods of use |
| CN114015770B (zh) * | 2021-12-30 | 2022-04-26 | 佛山市第三人民医院(佛山市精神卫生中心) | 精神分裂全外周血rna标志物fgfr3及其应用 |
| EP4619438A2 (en) * | 2022-11-14 | 2025-09-24 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| WO2024152014A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| IL159177A0 (en) * | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20070248605A1 (en) * | 2003-12-19 | 2007-10-25 | Five Prime Therapetutics, Inc. | Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention |
| EP2024394B1 (en) * | 2006-06-06 | 2014-11-05 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof |
| HRP20130163T1 (hr) * | 2006-09-07 | 2013-03-31 | Crucell Holland B.V. | Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba |
| WO2009054873A2 (en) * | 2007-08-02 | 2009-04-30 | Novimmune S.A. | Anti-rantes antibodies and methods of use thereof |
| KR102269708B1 (ko) * | 2008-04-11 | 2021-06-25 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2313435A4 (en) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
| TWI381848B (zh) * | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
-
2009
- 2009-10-05 TW TW098133737A patent/TWI381848B/zh not_active IP Right Cessation
- 2009-10-05 AR ARP090103832A patent/AR073770A1/es unknown
- 2009-10-15 JP JP2011532250A patent/JP5577345B2/ja not_active Expired - Fee Related
- 2009-10-15 CN CN201310384769.3A patent/CN103524620A/zh active Pending
- 2009-10-15 CN CN200980141656.2A patent/CN102186884B/zh not_active Expired - Fee Related
- 2009-10-15 KR KR1020117008935A patent/KR101370798B1/ko not_active Expired - Fee Related
- 2009-10-15 UA UAA201104814A patent/UA101681C2/ru unknown
- 2009-10-15 NZ NZ592369A patent/NZ592369A/xx not_active IP Right Cessation
- 2009-10-15 WO PCT/US2009/060840 patent/WO2010048026A2/en not_active Ceased
- 2009-10-15 CA CA2741127A patent/CA2741127C/en not_active Expired - Fee Related
- 2009-10-15 BR BRPI0919832A patent/BRPI0919832A8/pt not_active IP Right Cessation
- 2009-10-15 AU AU2009307841A patent/AU2009307841B2/en not_active Ceased
- 2009-10-15 US US12/579,825 patent/US8043618B2/en not_active Expired - Fee Related
- 2009-10-15 EA EA201170590A patent/EA021584B1/ru not_active IP Right Cessation
- 2009-10-15 EP EP09737319A patent/EP2342232A2/en not_active Ceased
- 2009-10-15 MX MX2011004317A patent/MX2011004317A/es active IP Right Grant
-
2011
- 2011-03-14 ZA ZA2011/01938A patent/ZA201101938B/en unknown
- 2011-03-17 IL IL211807A patent/IL211807A0/en unknown
- 2011-09-19 US US13/235,900 patent/US8182815B2/en not_active Expired - Fee Related
-
2012
- 2012-04-20 US US13/452,043 patent/US8404240B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA201170590A1 (ru) | 2011-10-31 |
| BRPI0919832A8 (pt) | 2019-01-08 |
| JP2012505912A (ja) | 2012-03-08 |
| US8404240B2 (en) | 2013-03-26 |
| WO2010048026A3 (en) | 2010-07-15 |
| MX2011004317A (es) | 2011-06-24 |
| CA2741127C (en) | 2015-06-02 |
| AU2009307841A1 (en) | 2010-04-29 |
| CN103524620A (zh) | 2014-01-22 |
| EA021584B1 (ru) | 2015-07-30 |
| EP2342232A2 (en) | 2011-07-13 |
| US20120009200A1 (en) | 2012-01-12 |
| CN102186884A (zh) | 2011-09-14 |
| US20120219563A1 (en) | 2012-08-30 |
| CN102186884B (zh) | 2014-08-13 |
| US8043618B2 (en) | 2011-10-25 |
| IL211807A0 (en) | 2011-06-30 |
| TW201026325A (en) | 2010-07-16 |
| WO2010048026A2 (en) | 2010-04-29 |
| TWI381848B (zh) | 2013-01-11 |
| UA101681C2 (ru) | 2013-04-25 |
| KR20110056554A (ko) | 2011-05-30 |
| NZ592369A (en) | 2013-02-22 |
| AU2009307841B2 (en) | 2013-09-12 |
| JP5577345B2 (ja) | 2014-08-20 |
| US20100098696A1 (en) | 2010-04-22 |
| ZA201101938B (en) | 2012-08-29 |
| KR101370798B1 (ko) | 2014-03-14 |
| BRPI0919832A2 (pt) | 2015-12-15 |
| CA2741127A1 (en) | 2010-04-29 |
| US8182815B2 (en) | 2012-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073770A1 (es) | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| ES2631135T3 (es) | Proteínas de unión a antígeno humanas que se unen a beta-Klotho, receptores de FGF y complejos de los mismos | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| ES2430068T3 (es) | Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina | |
| PE20191131A1 (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| NZ783685A (en) | Antibodies and conjugates thereof | |
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| PE20091674A1 (es) | Antagonistas del receptor de glucagon | |
| AR081556A1 (es) | Proteinas de union al antigeno humanizadas | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| NZ596274A (en) | Blocking anti-dkk-1 antibodies and their uses | |
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| AR061115A1 (es) | Anticuerpos anti- interleuquina 18 (il-18) | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| WO2012045481A3 (en) | Antibody targeting osteoclast-related protein siglec-15 | |
| PE20120554A1 (es) | Polipeptidos y metodo de tratamiento | |
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |